FDA panel endorses Johnson & Johnson's COVID-19 vaccine

Health Canada approves third COVID-19 vaccine

Health Canada approves third COVID-19 vaccine

That will be followed by an in-depth panel discussion and vote.

The long-anticipated J&J shot promises to offer the USA a third vaccine option and help speed vaccinations by requiring just one dose instead of two.

"There's an urgency to get this done", said Dr. Jay Portnoy of Children's Mercy Hospital in Kansas City, Mo. "Any further easing of COVID-19 restrictions should only be undertaken when all high-risk individuals in the province have been immunized - we have a short window remaining to prevent another surge and protect Albertans, but it is rapidly closing".

"This is the ideal vaccine for them", said Dr Scott Lindquist of the Washington State Department of Health.

Canada does not have domestic production and Trudeau's government has been accused of not obtaining vaccines fast enough even while also being criticized for ordering enough doses overall to supply its population 10 times over. Most of those shots are expected to arrive by the end of September.

More than half of Americans said they have already gotten at least one dose of the Covid-19 vaccine or want to get vaccinated as soon as possible, the Kaiser Family Foundationreported Friday.

This makes it slightly less protective than the Pfizer and Moderna's two-shot regimens, which both have an efficacy of around 95 percent against all forms of Covid-19 from the classic coronavirus strain.

Johnson & Johnson has announced it aims to deliver a total of 20 million doses by the end of March.

"So the thing about them is they're much easier to work with so they're just stored at fridge temperatures like we'd see with normal flu shots, they're also much easier to transport", said Kelly Grindrod, a professor at the University of Waterloo's School of Pharmacy.

One challenge in rolling out the new vaccine will be explaining how protective the J&J shot is after the astounding success of the first USA vaccines.

Health Canada approves third COVID-19 vaccine

There was a hint, based on preliminary data, that the vaccine might be effective against asymptomatic infection - though J&J said they need to do more research to confirm this.

Tam added that average daily case counts in Ontario, Alberta and British Columbia have increased between eight and 14 per cent over the previous week.

Some experts fear that lower number could feed public perceptions that J&J's shot is a "second-tier vaccine".

J&J's "robust" coronavirus vaccine generates a lasting immune response in an early-stage clinical trial.

Canada said it will make it available to people aged over 18. "There are, I understand, questions about the amount of evidence that we have for folks who are 65 and older so I look forward to getting that advice", said Shandro.

Meanwhile, Alberta reported 356 new case of COVID-19 on Friday after 9,212 tests were conducted.

While Tam warned that COVID-19 variants can spread more quickly and easily become dominant, progress on the vaccine front is a source of optimism, she noted.

"Most vaccine sites administer one [type of] vaccine on a given day", Manisha Juthani, an infectious-disease specialist at Yale Medicine, wrote in an email. An advisory panel of vaccine experts meets Friday to discuss the findings, with the FDA set to authorize the vaccine as early as Saturday.

Other parts of the world already are facing which-is-best challenges. AstraZeneca's vaccine, for instance, is cleared for use in Britain and Europe after data suggested it was about 70 percent effective.

The AstraZeneca and CoviShield COVID-19 vaccines are like the same recipe being prepared in two different kitchens.

Security officials cast blame for US Capitol riot
Irving, however, said he did not remember the discussion as a request, and flatly denied he had been concerned about appearances. Lawmakers spent considerable time questioning the security officials about delays in getting help from the National Guard.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.